High Tolerability in Thousands of Sessions
A comprehensive study conducted in 2025 analyzed data from 33 centers, focusing on 785 Alzheimer patients who underwent a remarkable total of 17,690 treatment sessions. The outcome was promising: no clinically significant side effects were observed. Only a handful of patients reported minor, temporary headaches. This suggests that the therapy is not just effective but also remarkably safe.
The analysis further indicated that the patients’ conditions did not worsen over the observation period. By mid-2026, around 290,000 TPS (Transcranial Pulse Stimulation) sessions had been documented globally. The standard procedure typically involves six initial treatments spaced out over two weeks, illustrating a well-structured approach to patient care.
How the Method Works
Transcranial Pulse Stimulation employs sound pulses that can penetrate up to eight centimeters deep into the brain tissue. Its goal is the non-invasive stimulation of specific brain areas, making it a gentle alternative to many invasive procedures. The availability of TPS has significantly increased, with over 250 clinics worldwide offering it, more than 100 of which are located in Germany, Austria, and Switzerland.
At Heinrich Heine University in Düsseldorf, a specialized Alzheimer registry has been established to systematically gather long-term data and support the scientific study of this clinical application. This registry plays a crucial role in understanding the long-term efficacy and safety of TPS.
Emerging Research Fields
Beyond its application for Alzheimer’s disease, researchers are exploring the potential of TPS in various other fields. The Medical University of Vienna is conducting a randomized, double-blind study involving 102 patients to examine the effectiveness of TPS in addressing Long-COVID conditions.
Additionally, Hong Kong’s University is running the largest single study to date with 180 participants, evaluating TPS’s application for attention disorders. These studies are essential in expanding the horizons of TPS, indicating its versatility and potential in treating diverse neurological conditions.
New findings in fundamental research also complement technological therapies. Biotechnologist Esther Hellmann from IMC Krems is investigating the Toll-Like Receptor 10 (TLR10) in microglia cells, suggesting that targeted modulation of this “inflammation brake” in the brain could offer innovative approaches to treating neurodegenerative diseases.
Medicated Context
The emergence of brain stimulation therapies coincides with a transformative period in the Alzheimer medication market. As of June 2026, the antibody therapies Lecanemab and Donanemab have become available in Germany, although they’re only suitable for a fraction—approximately 120,000 out of the 1.2 million affected patients. This scarcity underscores the need for complementary treatment options like TPS.
Mild and non-invasive, Transcranial Pulse Stimulation stands as a viable alternative for those not eligible for current antibody treatments. With over 100 clinics offering this option throughout Germany, Austria, and Switzerland, TPS presents itself as not just an alternative but a necessary addition to the existing therapeutic arsenal against Alzheimer’s disease and potentially other neurological disorders.
For further information on how TPS works and to locate a clinic near you, consider downloading our guide, which outlines the process and benefits of Transcranial Pulse Stimulation.
